Newmed Energy-limited Partnership, IL0004750209

NewMed Energy cancels USD 6.70 billion deal: what it means for NewMed Energy stock

Published on 10/13/2026 at 09:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter gas sales rose 52.90 percent to USD 293.20 million. NewMed Energy stock saw first-half profit fall 79.70 percent.

NewMed Energy reaffirmed the cancellation of a USD 6.70 billion gas supply agreement on October 7, 2026.
Second-quarter gas and condensate sales rose 52.90 percent to USD 293.20 million, while first-half net profit fell 79.70 percent to USD 117.90 million.
The TASE quote was ILA 1,571.00 on October 13, 2026, 31.40 percent below the ILA 2,290.00 52-week high.
NewMed Energy's next earnings date is November 12, 2026.

Newmed Energy-limited Partnership, IL0004750209, Illustration mit AI erstellt.

NewMed Energy canceled a USD 6.70 billion gas agreement and later reaffirmed that position on October 7, 2026, according to Globes. The dispute matters because NewMed holds 45.34 percent of the Leviathan gas field, leaving the contract question directly tied to its core asset exposure.

Three dates shape the dispute

On September 25, 2026, NewMed and Ratio canceled the USD 6.70 billion gas supply agreement, while the buyer challenged the validity of that notice, according to Deep TASE. On October 6, 2026, the Competition Authority approved the USD 6.70 billion agreement, a decision covered by Globes. On October 7, 2026, NewMed still maintained that the 20-year contract had been canceled, while the counterparty said it remained in force, according to Globes.

What does the dispute mean for cash flow?

The latest operating picture is mixed. Gas and condensate sales rose 52.90 percent year over year to USD 293.20 million in the second quarter of 2026, while consolidated net profit fell 79.70 percent to USD 117.90 million in the first half of 2026, according to Deep TASE. The report linked the profit decline to drilling costs and a Leviathan production halt, while higher sales volumes and prices supported the second-quarter revenue increase.

NewMed's separate Leviathan expansion financing reached USD 500.00 million, according to the same analysis. That distinction is important: the Dalia contract dispute affects a major future sales arrangement, while the partnership continues to finance development of its principal gas asset.

Next report arrives November 12

TradingView lists November 12, 2026, as NewMed Energy's next earnings date. The upcoming report should give investors a fresh reference point for production, sales and the financial effect of the contract dispute.

Stock remains below its yearly high

NewMed Energy traded at ILA 1,571.00 on the Tel Aviv Stock Exchange on October 13, 2026 at 10:10 a.m. IDT. Its ILA 18.4 billion market capitalization and ILA 1,534.00 to ILA 2,290.00 52-week range put the quote 31.40 percent below the yearly high.